Conatus pharmaceuticals inc. (CNAT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12
Revenues:
Collaboration revenue

0

526

3,376

10,791

7,024

7,409

7,666

8,774

9,737

-

9,566

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

10,008

6,998

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

0

526

3,376

10,791

7,024

7,409

7,666

8,774

9,737

8,805

9,566

10,008

6,998

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

66

833

4,746

8,565

9,383

8,886

9,664

10,737

12,081

10,911

11,165

13,218

7,926

6,523

4,825

4,246

4,698

4,240

4,103

4,070

3,883

3,393

4,397

3,467

3,650

2,976

1,885

1,117

967

1,774

1,119

General and administrative

3,533

2,538

2,013

3,054

2,591

2,528

2,660

2,594

2,713

2,301

2,449

2,194

2,763

3,453

2,069

2,238

2,576

1,799

1,958

1,994

2,081

1,927

2,018

1,837

1,595

2,123

1,107

670

748

737

649

Total operating expenses

3,599

3,371

6,759

11,619

11,974

11,414

12,324

13,331

14,794

13,212

13,614

15,412

10,689

9,976

6,894

6,484

7,274

6,039

6,061

6,064

5,964

5,321

6,416

5,304

5,245

5,100

2,993

1,787

1,716

2,511

1,768

Loss from operations

-3,599

-2,845

-3,383

-828

-4,950

-4,005

-4,658

-4,557

-5,057

-4,407

-4,048

-5,404

-3,691

-9,177

-6,894

-6,484

-7,274

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense):
Interest income

58

77

119

172

200

232

253

244

233

-

259

218

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

171

-

33

34

26

18

19

17

11

9

11

15

20

14

7

0

0

5

8

Interest expense

-

-

0

0

-

135

189

187

185

189

189

187

97

17

17

17

17

17

17

17

17

17

17

17

17

44

203

196

17

17

17

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

60

39

11

0

3

2

5

3

-9

-

-22

-44

-

28

11

-3

-6

-5

-8

6

-8

-7

-15

3

-0

5

7

0

-15

-4

-4

Other financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-139

-2,890

-547

-56

-44

Total other income

118

116

130

172

203

99

69

60

39

51

48

-13

68

53

27

13

2

-4

-6

7

-14

-15

-20

1

2

-24

-327

-3,085

-580

-72

-58

Net loss

-3,481

-2,729

-3,253

-656

-4,747

-3,906

-4,589

-4,497

-5,018

-4,356

-4,000

-5,417

-3,623

-9,124

-6,866

-6,471

-7,271

-6,044

-6,067

-6,057

-5,979

-5,336

-6,437

-5,303

-5,243

-5,125

-3,320

-4,873

-2,296

-2,584

-1,826

Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities

0

-1

-4

2

20

-5

29

71

-35

-54

-1

-3

-13

-14

-9

13

9

-4

10

-7

10

-6

-8

4

-13

-0

11

0

-0

-1

-0

Comprehensive loss

-3,481

-2,730

-3,257

-654

-4,727

-3,911

-4,560

-4,426

-5,053

-4,410

-4,001

-5,420

-3,636

-9,138

-6,876

-6,457

-7,262

-6,048

-6,056

-6,064

-5,968

-5,342

-6,446

-5,299

-5,256

-5,125

-3,309

-4,873

-2,297

-2,586

-1,827

Net loss

-3,481

-2,729

-3,253

-656

-4,747

-3,906

-4,589

-4,497

-5,018

-4,356

-4,000

-5,417

-3,623

-

-6,866

-6,471

-

-

-

-

-

-

-6,437

-5,303

-5,243

-5,125

-3,320

-4,873

-2,296

-2,584

-1,826

Gain on extinguishment of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

11,491

0

-

-

Deemed distribution from promissory note issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

474

0

-

-

Net income applicable to participating securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

793

-3,320

223

-2,296

-2,584

-1,826

Net loss per share, basic and diluted

-0.10

-0.08

-0.10

-0.02

-0.14

-0.12

-0.15

-0.15

-0.17

-0.15

-0.13

-0.19

-0.14

-0.35

-0.31

-0.30

-0.35

-0.30

-0.31

-0.31

-0.38

-0.34

-0.42

-0.34

-0.34

-

-0.28

-

-2.17

-

-

Weighted average shares outstanding used in computing net loss per share, basic and diluted

33,170

33,173

33,170

33,168

33,165

31,128

30,190

30,114

30,048

30,078

30,004

28,103

26,163

26,021

22,410

21,542

20,626

19,881

19,668

19,338

15,581

15,549

15,508

15,445

15,412

-

11,664

-

1,060

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2.55

-1.81

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2.55

-1.81

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,012

1,012

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,012

1,012